Adult Immune Thrombocytopenia Purpura

home / peer-exchange / adult-immune-thrombocytopenia-purpura

EP. 1: Adult ITP: Causes and Pathophysiology

January 27th 2020

EP. 2: Risks of Bleeding and Thrombosis in Adult ITP

January 27th 2020

EP. 3: Tests to Aid in the Diagnosis of Adult ITP

January 27th 2020

EP. 4: Adult ITP: When Is It Appropriate to Initiate Therapy?

January 27th 2020

EP. 5: Frontline Corticosteroid Strategies in Adult ITP

January 27th 2020

$2019 ASH Guideline Update on Treating Relapsed/Refractory ITP$

EP. 6: 2019 ASH Guideline Update on Treating Relapsed/Refractory ITP

January 27th 2020

EP. 7: Targeting Syk in Adult Immune Thrombocytopenic Purpura

January 27th 2020

EP. 8: Syk Inhibition in Adult ITP: The FIT1 and FIT2 Trials

January 27th 2020

EP. 9: Adult Immune Thrombocytopenic Purpura: TPO Receptor Agonists

January 27th 2020

EP. 10: Rituximab or Platelet Transfusion in ITP

January 27th 2020

EP. 11: Later-Line Treatment Options in Adult ITP

January 27th 2020

EP. 12: Adult ITP: Promising Therapeutic Agents in Development

January 27th 2020

EP. 13: Use of Splenectomy in Adult Immune Thrombocytopenic Purpura

January 27th 2020

Latest Conference Coverage

Axatilimab Elicits Responses With Manageable Safety in Recurrent/Refractory cGVHD

Dr Bal on Updated Findings With BMS-986393 in Relapsed/Refractory Multiple Myeloma

Dr Ghia on a Biomarker Analysis of the SEQUOIA Trial in CLL/SLL

Oral DEC-C Treatment Is Feasible and Comparable With IV/SC HMA Outcomes in MDS

View More Latest Conference Coverage

Do Not Sell My Information

Contact Info

2 Clarke Drive
Cranbury, NJ 08512